Compounding Pharmacies · Texas
The state board inspection scheduled for next month. Your renewal closes the week before.
Texas compounding pharmacies operate at the intersection of state board enforcement, USP 797/800 compliance, PBM network credentialing, and increasingly aggressive carrier endorsement schedules — including GLP-1 exclusions added without prominent disclosure at renewal.
We help 503A sterile and non-sterile compounders rebuild programs around druggist professional liability with adequate scope, products coverage that does not silently exclude their lines, and property coverage that responds to sterile-suite and hazardous-drug exposures.
Problem 01 · USP 797 compliance
Inspection-readiness drives underwriting.
Carriers underwriting sterile compounding require current USP 797 documentation as a condition of binding. The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; pharmacies that updated SOPs to comply have a smoother renewal experience than those that did not.
State board of pharmacy inspections also feed into underwriting. Form 483 observations, warning letters, and recent enforcement actions all factor into renewal pricing and availability.
Problem 02 · GLP-1 exclusions
The endorsement schedule changed silently.
Several specialty pharmacy carriers added exclusions for compounded versions of FDA-approved branded drugs (semaglutide, tirzepatide) starting in 2025-2026, often without prominent disclosure at renewal. A pharmacy compounding GLP-1s under a policy with this exclusion has uninsured products liability for that revenue line.
See the dedicated GLP-1 page for the full landscape.
Problem 03 · PBM network status
A lapsed COI silently terminates the network.
PBM network agreements (Express Scripts, CVS Caremark, OptumRx) require druggist professional liability and general liability minimums plus current COI on file. A 30-day notice of cancellation lapse can trigger silent network removal — dispensing continues but claims start getting denied, with the pharmacy often discovering the lapse only after weeks of accumulated denied revenue.
Reinstatement after administrative lapse is sometimes possible. Reinstatement after a claims-driven termination is much harder. Coverage discipline at renewal is the cheapest defense.
Frequently asked
Common questions from CDMO and CRO buyers
What insurance does a compounding pharmacy need?
+
Druggist professional liability, products liability, general liability, property (with sterile-suite or hazardous-drug peril if applicable), cyber for HIPAA exposure, and crime/fidelity. Sterile compounders need higher products limits.
How does USP 797 compliance affect my premium?
+
Carriers underwriting sterile compounding require current USP 797 documentation as a condition. Clean inspection history can earn credit; lapses trigger non-renewal or restrictive endorsements.
Does my insurance cover GLP-1 compounding?
+
Maybe not — many specialty pharmacy carriers added GLP-1 exclusions in 2025-2026. Read the endorsement schedule carefully. If you compound GLP-1s, the exclusion is often the most important line in the policy.
What is the difference between 503A and 503B insurance needs?
+
503A patient-specific compounding uses a pharmacy-classed program. 503B outsourcing-facility status requires manufacturer-classed coverage with cGMP property, higher products limits, and FDA-specific recall language.
How long does compounding pharmacy insurance underwriting take?
+
Specialty markets typically need 2-4 weeks for sterile/503B accounts. Underwriting requires USP 797 documentation, current state board inspection history, and 5 years of loss runs. Plan ahead of renewal.
Do I need separate cyber coverage?
+
Yes. Pharmacies hold significant PHI under HIPAA, and Texas HB300 adds state-level requirements. A standalone cyber policy with HIPAA notification expense coverage is standard.
Free coverage review